

Global Neuromyelitis Optica Drug Market 2024 by Company, Regions, Type and Application, Forecast to 2030

<https://marketpublishers.com/r/G1D536776DA9EN.html>

Date: January 2024

Pages: 118

Price: US\$ 3,480.00 (Single User License)

ID: G1D536776DA9EN

Abstracts

According to our (Global Info Research) latest study, the global Neuromyelitis Optica Drug market size was valued at USD 48 million in 2023 and is forecast to a readjusted size of USD 59 million by 2030 with a CAGR of 2.9% during review period.

Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.

Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.

Europe is the largest Neuromyelitis Optica Drug market with about 40% market share. North America is follower, accounting for about 35% market share.

The key players are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP etc. Top 3 companies occupied about 35% market share.

The Global Info Research report includes an overview of the development of the Neuromyelitis Optica Drug industry chain, the market status of Acute Attack (Glucocorticoids, Immunotherapies), Remission Prophylactic Treatment (Glucocorticoids, Immunotherapies), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Neuromyelitis Optica Drug.

Regionally, the report analyzes the Neuromyelitis Optica Drug markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Neuromyelitis Optica Drug market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:

The report presents comprehensive understanding of the Neuromyelitis Optica Drug market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Neuromyelitis Optica Drug industry.

The report involves analyzing the market at a macro level:

Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Glucocorticoids, Immunotherapies).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Neuromyelitis Optica Drug market.

Regional Analysis: The report involves examining the Neuromyelitis Optica Drug market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Neuromyelitis Optica Drug market. This may include

estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Neuromyelitis Optica Drug:

Company Analysis: Report covers individual Neuromyelitis Optica Drug players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Neuromyelitis Optica Drug. This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Acute Attack, Remission Prophylactic Treatment).

Technology Analysis: Report covers specific technologies relevant to Neuromyelitis Optica Drug. It assesses the current state, advancements, and potential future developments in Neuromyelitis Optica Drug areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report presents insights into the competitive landscape of the Neuromyelitis Optica Drug market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation

Neuromyelitis Optica Drug market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.

Market segment by Type

Glucocorticoids

Immunotherapies

Others

Market segment by Application

Acute Attack

Remission Prophylactic Treatment

Market segment by players, this report covers

Pfizer

Fresenius

Teva

Sandoz

Intas

Gyjtrs

NANG KUANG

Tianjin Kingyork

Baxter

CSL

Grifols

Octapharma

CBOP

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)

South America (Brazil, Argentina and Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Neuromyelitis Optica Drug product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Neuromyelitis Optica Drug, with revenue, gross margin and global market share of Neuromyelitis Optica Drug from 2019 to 2024.

Chapter 3, the Neuromyelitis Optica Drug competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024. and Neuromyelitis Optica Drug market forecast, by regions, type and application, with consumption value, from 2025 to 2030.

Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Neuromyelitis Optica Drug.

Chapter 13, to describe Neuromyelitis Optica Drug research findings and conclusion.

Contents

1 MARKET OVERVIEW

- 1.1 Product Overview and Scope of Neuromyelitis Optica Drug
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Classification of Neuromyelitis Optica Drug by Type
 - 1.3.1 Overview: Global Neuromyelitis Optica Drug Market Size by Type: 2019 Versus 2023 Versus 2030
 - 1.3.2 Global Neuromyelitis Optica Drug Consumption Value Market Share by Type in 2023
 - 1.3.3 Glucocorticoids
 - 1.3.4 Immunotherapies
 - 1.3.5 Others
- 1.4 Global Neuromyelitis Optica Drug Market by Application
 - 1.4.1 Overview: Global Neuromyelitis Optica Drug Market Size by Application: 2019 Versus 2023 Versus 2030
 - 1.4.2 Acute Attack
 - 1.4.3 Remission Prophylactic Treatment
- 1.5 Global Neuromyelitis Optica Drug Market Size & Forecast
- 1.6 Global Neuromyelitis Optica Drug Market Size and Forecast by Region
 - 1.6.1 Global Neuromyelitis Optica Drug Market Size by Region: 2019 VS 2023 VS 2030
 - 1.6.2 Global Neuromyelitis Optica Drug Market Size by Region, (2019-2030)
 - 1.6.3 North America Neuromyelitis Optica Drug Market Size and Prospect (2019-2030)
 - 1.6.4 Europe Neuromyelitis Optica Drug Market Size and Prospect (2019-2030)
 - 1.6.5 Asia-Pacific Neuromyelitis Optica Drug Market Size and Prospect (2019-2030)
 - 1.6.6 South America Neuromyelitis Optica Drug Market Size and Prospect (2019-2030)
 - 1.6.7 Middle East and Africa Neuromyelitis Optica Drug Market Size and Prospect (2019-2030)

2 COMPANY PROFILES

- 2.1 Pfizer
 - 2.1.1 Pfizer Details
 - 2.1.2 Pfizer Major Business
 - 2.1.3 Pfizer Neuromyelitis Optica Drug Product and Solutions
 - 2.1.4 Pfizer Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share

(2019-2024)

2.1.5 Pfizer Recent Developments and Future Plans

2.2 Fresenius

2.2.1 Fresenius Details

2.2.2 Fresenius Major Business

2.2.3 Fresenius Neuromyelitis Optica Drug Product and Solutions

2.2.4 Fresenius Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share

(2019-2024)

2.2.5 Fresenius Recent Developments and Future Plans

2.3 Teva

2.3.1 Teva Details

2.3.2 Teva Major Business

2.3.3 Teva Neuromyelitis Optica Drug Product and Solutions

2.3.4 Teva Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share

(2019-2024)

2.3.5 Teva Recent Developments and Future Plans

2.4 Sandoz

2.4.1 Sandoz Details

2.4.2 Sandoz Major Business

2.4.3 Sandoz Neuromyelitis Optica Drug Product and Solutions

2.4.4 Sandoz Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share

(2019-2024)

2.4.5 Sandoz Recent Developments and Future Plans

2.5 Intas

2.5.1 Intas Details

2.5.2 Intas Major Business

2.5.3 Intas Neuromyelitis Optica Drug Product and Solutions

2.5.4 Intas Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share

(2019-2024)

2.5.5 Intas Recent Developments and Future Plans

2.6 Gyjtrs

2.6.1 Gyjtrs Details

2.6.2 Gyjtrs Major Business

2.6.3 Gyjtrs Neuromyelitis Optica Drug Product and Solutions

2.6.4 Gyjtrs Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share

(2019-2024)

2.6.5 Gyjtrs Recent Developments and Future Plans

2.7 NANG KUANG

2.7.1 NANG KUANG Details

- 2.7.2 NANG KUANG Major Business
- 2.7.3 NANG KUANG Neuromyelitis Optica Drug Product and Solutions
- 2.7.4 NANG KUANG Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2019-2024)
- 2.7.5 NANG KUANG Recent Developments and Future Plans
- 2.8 Tianjin Kingyork
 - 2.8.1 Tianjin Kingyork Details
 - 2.8.2 Tianjin Kingyork Major Business
 - 2.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Product and Solutions
 - 2.8.4 Tianjin Kingyork Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2019-2024)
 - 2.8.5 Tianjin Kingyork Recent Developments and Future Plans
- 2.9 Baxter
 - 2.9.1 Baxter Details
 - 2.9.2 Baxter Major Business
 - 2.9.3 Baxter Neuromyelitis Optica Drug Product and Solutions
 - 2.9.4 Baxter Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2019-2024)
 - 2.9.5 Baxter Recent Developments and Future Plans
- 2.10 CSL
 - 2.10.1 CSL Details
 - 2.10.2 CSL Major Business
 - 2.10.3 CSL Neuromyelitis Optica Drug Product and Solutions
 - 2.10.4 CSL Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2019-2024)
 - 2.10.5 CSL Recent Developments and Future Plans
- 2.11 Grifols
 - 2.11.1 Grifols Details
 - 2.11.2 Grifols Major Business
 - 2.11.3 Grifols Neuromyelitis Optica Drug Product and Solutions
 - 2.11.4 Grifols Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2019-2024)
 - 2.11.5 Grifols Recent Developments and Future Plans
- 2.12 Octapharma
 - 2.12.1 Octapharma Details
 - 2.12.2 Octapharma Major Business
 - 2.12.3 Octapharma Neuromyelitis Optica Drug Product and Solutions
 - 2.12.4 Octapharma Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2019-2024)

- 2.12.5 Octapharma Recent Developments and Future Plans
- 2.13 CBOP
 - 2.13.1 CBOP Details
 - 2.13.2 CBOP Major Business
 - 2.13.3 CBOP Neuromyelitis Optica Drug Product and Solutions
 - 2.13.4 CBOP Neuromyelitis Optica Drug Revenue, Gross Margin and Market Share (2019-2024)
 - 2.13.5 CBOP Recent Developments and Future Plans

3 MARKET COMPETITION, BY PLAYERS

- 3.1 Global Neuromyelitis Optica Drug Revenue and Share by Players (2019-2024)
- 3.2 Market Share Analysis (2023)
 - 3.2.1 Market Share of Neuromyelitis Optica Drug by Company Revenue
 - 3.2.2 Top 3 Neuromyelitis Optica Drug Players Market Share in 2023
 - 3.2.3 Top 6 Neuromyelitis Optica Drug Players Market Share in 2023
- 3.3 Neuromyelitis Optica Drug Market: Overall Company Footprint Analysis
 - 3.3.1 Neuromyelitis Optica Drug Market: Region Footprint
 - 3.3.2 Neuromyelitis Optica Drug Market: Company Product Type Footprint
 - 3.3.3 Neuromyelitis Optica Drug Market: Company Product Application Footprint
- 3.4 New Market Entrants and Barriers to Market Entry
- 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 MARKET SIZE SEGMENT BY TYPE

- 4.1 Global Neuromyelitis Optica Drug Consumption Value and Market Share by Type (2019-2024)
- 4.2 Global Neuromyelitis Optica Drug Market Forecast by Type (2025-2030)

5 MARKET SIZE SEGMENT BY APPLICATION

- 5.1 Global Neuromyelitis Optica Drug Consumption Value Market Share by Application (2019-2024)
- 5.2 Global Neuromyelitis Optica Drug Market Forecast by Application (2025-2030)

6 NORTH AMERICA

- 6.1 North America Neuromyelitis Optica Drug Consumption Value by Type (2019-2030)
- 6.2 North America Neuromyelitis Optica Drug Consumption Value by Application

(2019-2030)

6.3 North America Neuromyelitis Optica Drug Market Size by Country

6.3.1 North America Neuromyelitis Optica Drug Consumption Value by Country

(2019-2030)

6.3.2 United States Neuromyelitis Optica Drug Market Size and Forecast (2019-2030)

6.3.3 Canada Neuromyelitis Optica Drug Market Size and Forecast (2019-2030)

6.3.4 Mexico Neuromyelitis Optica Drug Market Size and Forecast (2019-2030)

7 EUROPE

7.1 Europe Neuromyelitis Optica Drug Consumption Value by Type (2019-2030)

7.2 Europe Neuromyelitis Optica Drug Consumption Value by Application (2019-2030)

7.3 Europe Neuromyelitis Optica Drug Market Size by Country

7.3.1 Europe Neuromyelitis Optica Drug Consumption Value by Country (2019-2030)

7.3.2 Germany Neuromyelitis Optica Drug Market Size and Forecast (2019-2030)

7.3.3 France Neuromyelitis Optica Drug Market Size and Forecast (2019-2030)

7.3.4 United Kingdom Neuromyelitis Optica Drug Market Size and Forecast

(2019-2030)

7.3.5 Russia Neuromyelitis Optica Drug Market Size and Forecast (2019-2030)

7.3.6 Italy Neuromyelitis Optica Drug Market Size and Forecast (2019-2030)

8 ASIA-PACIFIC

8.1 Asia-Pacific Neuromyelitis Optica Drug Consumption Value by Type (2019-2030)

8.2 Asia-Pacific Neuromyelitis Optica Drug Consumption Value by Application
(2019-2030)

8.3 Asia-Pacific Neuromyelitis Optica Drug Market Size by Region

8.3.1 Asia-Pacific Neuromyelitis Optica Drug Consumption Value by Region

(2019-2030)

8.3.2 China Neuromyelitis Optica Drug Market Size and Forecast (2019-2030)

8.3.3 Japan Neuromyelitis Optica Drug Market Size and Forecast (2019-2030)

8.3.4 South Korea Neuromyelitis Optica Drug Market Size and Forecast (2019-2030)

8.3.5 India Neuromyelitis Optica Drug Market Size and Forecast (2019-2030)

8.3.6 Southeast Asia Neuromyelitis Optica Drug Market Size and Forecast

(2019-2030)

8.3.7 Australia Neuromyelitis Optica Drug Market Size and Forecast (2019-2030)

9 SOUTH AMERICA

- 9.1 South America Neuromyelitis Optica Drug Consumption Value by Type (2019-2030)
- 9.2 South America Neuromyelitis Optica Drug Consumption Value by Application (2019-2030)
- 9.3 South America Neuromyelitis Optica Drug Market Size by Country
 - 9.3.1 South America Neuromyelitis Optica Drug Consumption Value by Country (2019-2030)
 - 9.3.2 Brazil Neuromyelitis Optica Drug Market Size and Forecast (2019-2030)
 - 9.3.3 Argentina Neuromyelitis Optica Drug Market Size and Forecast (2019-2030)

10 MIDDLE EAST & AFRICA

- 10.1 Middle East & Africa Neuromyelitis Optica Drug Consumption Value by Type (2019-2030)
- 10.2 Middle East & Africa Neuromyelitis Optica Drug Consumption Value by Application (2019-2030)
- 10.3 Middle East & Africa Neuromyelitis Optica Drug Market Size by Country
 - 10.3.1 Middle East & Africa Neuromyelitis Optica Drug Consumption Value by Country (2019-2030)
 - 10.3.2 Turkey Neuromyelitis Optica Drug Market Size and Forecast (2019-2030)
 - 10.3.3 Saudi Arabia Neuromyelitis Optica Drug Market Size and Forecast (2019-2030)
 - 10.3.4 UAE Neuromyelitis Optica Drug Market Size and Forecast (2019-2030)

11 MARKET DYNAMICS

- 11.1 Neuromyelitis Optica Drug Market Drivers
- 11.2 Neuromyelitis Optica Drug Market Restraints
- 11.3 Neuromyelitis Optica Drug Trends Analysis
- 11.4 Porters Five Forces Analysis
 - 11.4.1 Threat of New Entrants
 - 11.4.2 Bargaining Power of Suppliers
 - 11.4.3 Bargaining Power of Buyers
 - 11.4.4 Threat of Substitutes
 - 11.4.5 Competitive Rivalry

12 INDUSTRY CHAIN ANALYSIS

- 12.1 Neuromyelitis Optica Drug Industry Chain
- 12.2 Neuromyelitis Optica Drug Upstream Analysis
- 12.3 Neuromyelitis Optica Drug Midstream Analysis

12.4 Neuromyelitis Optica Drug Downstream Analysis

13 RESEARCH FINDINGS AND CONCLUSION

14 APPENDIX

14.1 Methodology

14.2 Research Process and Data Source

14.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Neuromyelitis Optica Drug Consumption Value by Type, (USD Million), 2019 & 2023 & 2030

Table 2. Global Neuromyelitis Optica Drug Consumption Value by Application, (USD Million), 2019 & 2023 & 2030

Table 3. Global Neuromyelitis Optica Drug Consumption Value by Region (2019-2024) & (USD Million)

Table 4. Global Neuromyelitis Optica Drug Consumption Value by Region (2025-2030) & (USD Million)

Table 5. Pfizer Company Information, Head Office, and Major Competitors

Table 6. Pfizer Major Business

Table 7. Pfizer Neuromyelitis Optica Drug Product and Solutions

Table 8. Pfizer Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 9. Pfizer Recent Developments and Future Plans

Table 10. Fresenius Company Information, Head Office, and Major Competitors

Table 11. Fresenius Major Business

Table 12. Fresenius Neuromyelitis Optica Drug Product and Solutions

Table 13. Fresenius Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 14. Fresenius Recent Developments and Future Plans

Table 15. Teva Company Information, Head Office, and Major Competitors

Table 16. Teva Major Business

Table 17. Teva Neuromyelitis Optica Drug Product and Solutions

Table 18. Teva Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 19. Teva Recent Developments and Future Plans

Table 20. Sandoz Company Information, Head Office, and Major Competitors

Table 21. Sandoz Major Business

Table 22. Sandoz Neuromyelitis Optica Drug Product and Solutions

Table 23. Sandoz Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 24. Sandoz Recent Developments and Future Plans

Table 25. Intas Company Information, Head Office, and Major Competitors

Table 26. Intas Major Business

Table 27. Intas Neuromyelitis Optica Drug Product and Solutions

Table 28. Intas Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 29. Intas Recent Developments and Future Plans

Table 30. Gyjtrs Company Information, Head Office, and Major Competitors

Table 31. Gyjtrs Major Business

Table 32. Gyjtrs Neuromyelitis Optica Drug Product and Solutions

Table 33. Gyjtrs Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 34. Gyjtrs Recent Developments and Future Plans

Table 35. NANG KUANG Company Information, Head Office, and Major Competitors

Table 36. NANG KUANG Major Business

Table 37. NANG KUANG Neuromyelitis Optica Drug Product and Solutions

Table 38. NANG KUANG Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 39. NANG KUANG Recent Developments and Future Plans

Table 40. Tianjin Kingyork Company Information, Head Office, and Major Competitors

Table 41. Tianjin Kingyork Major Business

Table 42. Tianjin Kingyork Neuromyelitis Optica Drug Product and Solutions

Table 43. Tianjin Kingyork Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 44. Tianjin Kingyork Recent Developments and Future Plans

Table 45. Baxter Company Information, Head Office, and Major Competitors

Table 46. Baxter Major Business

Table 47. Baxter Neuromyelitis Optica Drug Product and Solutions

Table 48. Baxter Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 49. Baxter Recent Developments and Future Plans

Table 50. CSL Company Information, Head Office, and Major Competitors

Table 51. CSL Major Business

Table 52. CSL Neuromyelitis Optica Drug Product and Solutions

Table 53. CSL Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 54. CSL Recent Developments and Future Plans

Table 55. Grifols Company Information, Head Office, and Major Competitors

Table 56. Grifols Major Business

Table 57. Grifols Neuromyelitis Optica Drug Product and Solutions

Table 58. Grifols Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 59. Grifols Recent Developments and Future Plans

Table 60. Octapharma Company Information, Head Office, and Major Competitors

Table 61. Octapharma Major Business

Table 62. Octapharma Neuromyelitis Optica Drug Product and Solutions

Table 63. Octapharma Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 64. Octapharma Recent Developments and Future Plans

Table 65. CBOP Company Information, Head Office, and Major Competitors

Table 66. CBOP Major Business

Table 67. CBOP Neuromyelitis Optica Drug Product and Solutions

Table 68. CBOP Neuromyelitis Optica Drug Revenue (USD Million), Gross Margin and Market Share (2019-2024)

Table 69. CBOP Recent Developments and Future Plans

Table 70. Global Neuromyelitis Optica Drug Revenue (USD Million) by Players (2019-2024)

Table 71. Global Neuromyelitis Optica Drug Revenue Share by Players (2019-2024)

Table 72. Breakdown of Neuromyelitis Optica Drug by Company Type (Tier 1, Tier 2, and Tier 3)

Table 73. Market Position of Players in Neuromyelitis Optica Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023

Table 74. Head Office of Key Neuromyelitis Optica Drug Players

Table 75. Neuromyelitis Optica Drug Market: Company Product Type Footprint

Table 76. Neuromyelitis Optica Drug Market: Company Product Application Footprint

Table 77. Neuromyelitis Optica Drug New Market Entrants and Barriers to Market Entry

Table 78. Neuromyelitis Optica Drug Mergers, Acquisition, Agreements, and Collaborations

Table 79. Global Neuromyelitis Optica Drug Consumption Value (USD Million) by Type (2019-2024)

Table 80. Global Neuromyelitis Optica Drug Consumption Value Share by Type (2019-2024)

Table 81. Global Neuromyelitis Optica Drug Consumption Value Forecast by Type (2025-2030)

Table 82. Global Neuromyelitis Optica Drug Consumption Value by Application (2019-2024)

Table 83. Global Neuromyelitis Optica Drug Consumption Value Forecast by Application (2025-2030)

Table 84. North America Neuromyelitis Optica Drug Consumption Value by Type (2019-2024) & (USD Million)

Table 85. North America Neuromyelitis Optica Drug Consumption Value by Type (2025-2030) & (USD Million)

Table 86. North America Neuromyelitis Optica Drug Consumption Value by Application (2019-2024) & (USD Million)

Table 87. North America Neuromyelitis Optica Drug Consumption Value by Application (2025-2030) & (USD Million)

Table 88. North America Neuromyelitis Optica Drug Consumption Value by Country (2019-2024) & (USD Million)

Table 89. North America Neuromyelitis Optica Drug Consumption Value by Country (2025-2030) & (USD Million)

Table 90. Europe Neuromyelitis Optica Drug Consumption Value by Type (2019-2024) & (USD Million)

Table 91. Europe Neuromyelitis Optica Drug Consumption Value by Type (2025-2030) & (USD Million)

Table 92. Europe Neuromyelitis Optica Drug Consumption Value by Application (2019-2024) & (USD Million)

Table 93. Europe Neuromyelitis Optica Drug Consumption Value by Application (2025-2030) & (USD Million)

Table 94. Europe Neuromyelitis Optica Drug Consumption Value by Country (2019-2024) & (USD Million)

Table 95. Europe Neuromyelitis Optica Drug Consumption Value by Country (2025-2030) & (USD Million)

Table 96. Asia-Pacific Neuromyelitis Optica Drug Consumption Value by Type (2019-2024) & (USD Million)

Table 97. Asia-Pacific Neuromyelitis Optica Drug Consumption Value by Type (2025-2030) & (USD Million)

Table 98. Asia-Pacific Neuromyelitis Optica Drug Consumption Value by Application (2019-2024) & (USD Million)

Table 99. Asia-Pacific Neuromyelitis Optica Drug Consumption Value by Application (2025-2030) & (USD Million)

Table 100. Asia-Pacific Neuromyelitis Optica Drug Consumption Value by Region (2019-2024) & (USD Million)

Table 101. Asia-Pacific Neuromyelitis Optica Drug Consumption Value by Region (2025-2030) & (USD Million)

Table 102. South America Neuromyelitis Optica Drug Consumption Value by Type (2019-2024) & (USD Million)

Table 103. South America Neuromyelitis Optica Drug Consumption Value by Type (2025-2030) & (USD Million)

Table 104. South America Neuromyelitis Optica Drug Consumption Value by Application (2019-2024) & (USD Million)

Table 105. South America Neuromyelitis Optica Drug Consumption Value by

Application (2025-2030) & (USD Million)

Table 106. South America Neuromyelitis Optica Drug Consumption Value by Country (2019-2024) & (USD Million)

Table 107. South America Neuromyelitis Optica Drug Consumption Value by Country (2025-2030) & (USD Million)

Table 108. Middle East & Africa Neuromyelitis Optica Drug Consumption Value by Type (2019-2024) & (USD Million)

Table 109. Middle East & Africa Neuromyelitis Optica Drug Consumption Value by Type (2025-2030) & (USD Million)

Table 110. Middle East & Africa Neuromyelitis Optica Drug Consumption Value by Application (2019-2024) & (USD Million)

Table 111. Middle East & Africa Neuromyelitis Optica Drug Consumption Value by Application (2025-2030) & (USD Million)

Table 112. Middle East & Africa Neuromyelitis Optica Drug Consumption Value by Country (2019-2024) & (USD Million)

Table 113. Middle East & Africa Neuromyelitis Optica Drug Consumption Value by Country (2025-2030) & (USD Million)

Table 114. Neuromyelitis Optica Drug Raw Material

Table 115. Key Suppliers of Neuromyelitis Optica Drug Raw Materials

List Of Figures

LIST OF FIGURES

Figure 1. Neuromyelitis Optica Drug Picture

Figure 2. Global Neuromyelitis Optica Drug Consumption Value by Type, (USD Million), 2019 & 2023 & 2030

Figure 3. Global Neuromyelitis Optica Drug Consumption Value Market Share by Type in 2023

Figure 4. Glucocorticoids

Figure 5. Immunotherapies

Figure 6. Others

Figure 7. Global Neuromyelitis Optica Drug Consumption Value by Type, (USD Million), 2019 & 2023 & 2030

Figure 8. Neuromyelitis Optica Drug Consumption Value Market Share by Application in 2023

Figure 9. Acute Attack Picture

Figure 10. Remission Prophylactic Treatment Picture

Figure 11. Global Neuromyelitis Optica Drug Consumption Value, (USD Million): 2019 & 2023 & 2030

Figure 12. Global Neuromyelitis Optica Drug Consumption Value and Forecast (2019-2030) & (USD Million)

Figure 13. Global Market Neuromyelitis Optica Drug Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)

Figure 14. Global Neuromyelitis Optica Drug Consumption Value Market Share by Region (2019-2030)

Figure 15. Global Neuromyelitis Optica Drug Consumption Value Market Share by Region in 2023

Figure 16. North America Neuromyelitis Optica Drug Consumption Value (2019-2030) & (USD Million)

Figure 17. Europe Neuromyelitis Optica Drug Consumption Value (2019-2030) & (USD Million)

Figure 18. Asia-Pacific Neuromyelitis Optica Drug Consumption Value (2019-2030) & (USD Million)

Figure 19. South America Neuromyelitis Optica Drug Consumption Value (2019-2030) & (USD Million)

Figure 20. Middle East and Africa Neuromyelitis Optica Drug Consumption Value (2019-2030) & (USD Million)

Figure 21. Global Neuromyelitis Optica Drug Revenue Share by Players in 2023

Figure 22. Neuromyelitis Optica Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023

Figure 23. Global Top 3 Players Neuromyelitis Optica Drug Market Share in 2023

Figure 24. Global Top 6 Players Neuromyelitis Optica Drug Market Share in 2023

Figure 25. Global Neuromyelitis Optica Drug Consumption Value Share by Type (2019-2024)

Figure 26. Global Neuromyelitis Optica Drug Market Share Forecast by Type (2025-2030)

Figure 27. Global Neuromyelitis Optica Drug Consumption Value Share by Application (2019-2024)

Figure 28. Global Neuromyelitis Optica Drug Market Share Forecast by Application (2025-2030)

Figure 29. North America Neuromyelitis Optica Drug Consumption Value Market Share by Type (2019-2030)

Figure 30. North America Neuromyelitis Optica Drug Consumption Value Market Share by Application (2019-2030)

Figure 31. North America Neuromyelitis Optica Drug Consumption Value Market Share by Country (2019-2030)

Figure 32. United States Neuromyelitis Optica Drug Consumption Value (2019-2030) & (USD Million)

Figure 33. Canada Neuromyelitis Optica Drug Consumption Value (2019-2030) & (USD Million)

Figure 34. Mexico Neuromyelitis Optica Drug Consumption Value (2019-2030) & (USD Million)

Figure 35. Europe Neuromyelitis Optica Drug Consumption Value Market Share by Type (2019-2030)

Figure 36. Europe Neuromyelitis Optica Drug Consumption Value Market Share by Application (2019-2030)

Figure 37. Europe Neuromyelitis Optica Drug Consumption Value Market Share by Country (2019-2030)

Figure 38. Germany Neuromyelitis Optica Drug Consumption Value (2019-2030) & (USD Million)

Figure 39. France Neuromyelitis Optica Drug Consumption Value (2019-2030) & (USD Million)

Figure 40. United Kingdom Neuromyelitis Optica Drug Consumption Value (2019-2030) & (USD Million)

Figure 41. Russia Neuromyelitis Optica Drug Consumption Value (2019-2030) & (USD Million)

Figure 42. Italy Neuromyelitis Optica Drug Consumption Value (2019-2030) & (USD Million)

Million)

Figure 43. Asia-Pacific Neuromyelitis Optica Drug Consumption Value Market Share by Type (2019-2030)

Figure 44. Asia-Pacific Neuromyelitis Optica Drug Consumption Value Market Share by Application (2019-2030)

Figure 45. Asia-Pacific Neuromyelitis Optica Drug Consumption Value Market Share by Region (2019-2030)

Figure 46. China Neuromyelitis Optica Drug Consumption Value (2019-2030) & (USD Million)

Figure 47. Japan Neuromyelitis Optica Drug Consumption Value (2019-2030) & (USD Million)

Figure 48. South Korea Neuromyelitis Optica Drug Consumption Value (2019-2030) & (USD Million)

Figure 49. India Neuromyelitis Optica Drug Consumption Value (2019-2030) & (USD Million)

Figure 50. Southeast Asia Neuromyelitis Optica Drug Consumption Value (2019-2030) & (USD Million)

Figure 51. Australia Neuromyelitis Optica Drug Consumption Value (2019-2030) & (USD Million)

Figure 52. South America Neuromyelitis Optica Drug Consumption Value Market Share by Type (2019-2030)

Figure 53. South America Neuromyelitis Optica Drug Consumption Value Market Share by Application (2019-2030)

Figure 54. South America Neuromyelitis Optica Drug Consumption Value Market Share by Country (2019-2030)

Figure 55. Brazil Neuromyelitis Optica Drug Consumption Value (2019-2030) & (USD Million)

Figure 56. Argentina Neuromyelitis Optica Drug Consumption Value (2019-2030) & (USD Million)

Figure 57. Middle East and Africa Neuromyelitis Optica Drug Consumption Value Market Share by Type (2019-2030)

Figure 58. Middle East and Africa Neuromyelitis Optica Drug Consumption Value Market Share by Application (2019-2030)

Figure 59. Middle East and Africa Neuromyelitis Optica Drug Consumption Value Market Share by Country (2019-2030)

Figure 60. Turkey Neuromyelitis Optica Drug Consumption Value (2019-2030) & (USD Million)

Figure 61. Saudi Arabia Neuromyelitis Optica Drug Consumption Value (2019-2030) & (USD Million)

Figure 62. UAE Neuromyelitis Optica Drug Consumption Value (2019-2030) & (USD Million)

Figure 63. Neuromyelitis Optica Drug Market Drivers

Figure 64. Neuromyelitis Optica Drug Market Restraints

Figure 65. Neuromyelitis Optica Drug Market Trends

Figure 66. Porters Five Forces Analysis

Figure 67. Manufacturing Cost Structure Analysis of Neuromyelitis Optica Drug in 2023

Figure 68. Manufacturing Process Analysis of Neuromyelitis Optica Drug

Figure 69. Neuromyelitis Optica Drug Industrial Chain

Figure 70. Methodology

Figure 71. Research Process and Data Source

I would like to order

Product name: Global Neuromyelitis Optica Drug Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Product link: <https://marketpublishers.com/r/G1D536776DA9EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G1D536776DA9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

